Valuation: Insmed Incorporated

Market Cap 25.25B 22.28B 21.08B 19.12B 35.85B 2,423B 36.2B 253B 97.48B 1,237B 94.82B 92.76B 3,982B P/E 2026 *
-70.9x
P/E 2027 * 166x
Enterprise Value 24.62B 21.73B 20.56B 18.64B 34.95B 2,362B 35.3B 247B 95.04B 1,206B 92.45B 90.44B 3,882B EV / Sales 2026 *
13.6x
EV / Sales 2027 * 8.38x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-1.73%
1 week-4.30%
Current month-5.08%
1 month-2.45%
3 months+10.40%
6 months-20.42%
Current year-33.56%
1 week 114.49
Extreme 114.49
122.9
1 month 114.49
Extreme 114.49
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.61%+2.06%+38.30%+82.78% 60.12B
+4.77%+6.16%+36.77%+26.10% 27.98B
-0.51%-2.28%+0.48%-9.27% 24.76B
+1.04%+2.27%+21.61%-4.09% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+2.96%+0.83%-5.25%+519.59% 14.41B
+5.88%-4.26%-22.54%+776.47% 13.08B
Average +1.05%-1.14%+30.71%+234.22% 28.82B
Weighted average by Cap. +0.66%-1.64%+34.16%+159.44%

Financials

2026 *2027 *
Net sales 1.81B 1.6B 1.51B 1.37B 2.57B 173B 2.59B 18.11B 6.98B 88.59B 6.79B 6.64B 285B 2.88B 2.54B 2.4B 2.18B 4.08B 276B 4.12B 28.8B 11.1B 141B 10.8B 10.56B 453B
Net income -350M -309M -292M -265M -497M -33.56B -501M -3.5B -1.35B -17.14B -1.31B -1.28B -55.15B 182M 160M 152M 138M 258M 17.43B 260M 1.82B 701M 8.9B 682M 667M 28.64B
Net Debt -632M -558M -528M -478M -897M -60.63B -906M -6.33B -2.44B -30.96B -2.37B -2.32B -99.63B -1.16B -1.02B -966M -876M -1.64B -111B -1.66B -11.59B -4.47B -56.67B -4.34B -4.25B -182B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
29/09/26 $115.63 -1.73% 1,668,367
28/09/26 $117.67 -0.14% 1,744,370
25/09/26 $117.83 -3.06% 2,672,745
24/09/26 $121.55 +2.71% 2,233,624
23/09/26 $118.34 -2.05% 1,921,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
115.63USD
Average target price
197.74USD
Spread / Average Target
+71.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock